Eli Lilly and Company Stock News
$915.04
1.11%
yesterday
NYSE,
Sep 19, 10:14 pm CET
Eli Lilly and Company Stock News
Positive
Barrons
●
21 days ago
The GLP-1 drug giant's shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and Zepbound.
Neutral
The Motley Fool
●
21 days ago
Eli Lilly has been rolling out Zepbound in recent months, and demand has been "unbelievable," says the CEO. Sales have been taking off, and that's even without spending aggressively on sales and marketing.
Positive
Finbold
●
22 days ago
Achieving a $1 trillion market capitalization has long been a prestigious milestone in the stock market, with many companies striving to reach this level.
Positive
The Motley Fool
●
22 days ago
Lilly is making its obesity drug Zepbound available at less than half the cost of the list price of other GLP-1 drugs. The move is brilliant because it should expand the potential market for Zepbound.
Negative
Investors Business Daily
●
23 days ago
The idea with the trade is that if Eli Lilly stock remains around 950 for the next few weeks, the sold option will decay faster than the bought option.
Negative
The Motley Fool
●
23 days ago
Eli Lilly is exploring whether its newest hit drug could be used to treat psoriasis. AbbVie's newest hit drugs already treat psoriasis, among other conditions.
Neutral
Fast Company
●
23 days ago
Eli Lilly said it has begun selling vials of the smallest, starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month on its direct-to-consumer website to try to increase supplies in the marketplace.
Negative
Investopedia
●
24 days ago
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
